162
Participants
Start Date
June 30, 2006
Primary Completion Date
January 31, 2010
Study Completion Date
January 31, 2012
erlotinib
erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
sunitinib
Sunitinib 37.5 mg daily by oral capsule in a continuous regimen plus erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
erlotinib
erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
placebo
Placebo daily by oral capsule in a continuous regimen plus erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
Pfizer Investigational Site, Budapest
Pfizer Investigational Site, Törökbálint
Pfizer Investigational Site, Genova
Pfizer Investigational Site, Goldsboro
Pfizer Investigational Site, Wilson
Pfizer Investigational Site, Clinton
Pfizer Investigational Site, Bucharest
Pfizer Investigational Site, Birmingham
Pfizer Investigational Site, Birmingham
Pfizer Investigational Site, Mobile
Pfizer Investigational Site, Santander
Pfizer Investigational Site, Cleveland
Pfizer Investigational Site, Chicago
Pfizer Investigational Site, St Louis
Pfizer Investigational Site, Creve Coeur
Pfizer Investigational Site, City of Saint Peters
Pfizer Investigational Site, Houston
Pfizer Investigational Site, Monteforte Irpino, AV
Pfizer Investigational Site, Pleasant Hill
Pfizer Investigational Site, Antioch
Pfizer Investigational Site, San Leandro
Pfizer Investigational Site, Cluj-Napoca
Pfizer Investigational Site, Palm Springs
Pfizer Investigational Site, St Louis
Pfizer Investigational Site, Chapel Hill
Pfizer Investigational Site, Edmonton
Pfizer Investigational Site, Hamilton
Pfizer Investigational Site, Amsterdam
Pfizer Investigational Site, Groningen
Pfizer Investigational Site, Bydgoszcz
Pfizer Investigational Site, Gdansk
Pfizer Investigational Site, Bucharest
Lead Sponsor
Pfizer
INDUSTRY